Bayer（BAYN）株式概要
バイエルはライフサイエンス企業として世界中で事業を展開している。 詳細
報酬
リスク分析
リスクチェックの結果、BAYN 、リスクは検出されなかった。
BAYN Community Fair Values
Create NarrativeSee what 257 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
€40
FV
11.6% 割安 内在価値ディスカウント160
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Bayer Aktiengesellschaft 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €35.37 |
| 52週高値 | €49.78 |
| 52週安値 | €24.81 |
| ベータ | 0.84 |
| 1ヶ月の変化 | -4.61% |
| 3ヶ月変化 | -9.61% |
| 1年変化 | 27.44% |
| 3年間の変化 | -31.72% |
| 5年間の変化 | -33.59% |
| IPOからの変化 | 159.70% |
最新ニュース
Recent updates
ナラティブの更新 • Jun 06
BAYN: Litigation Resolution And Key Drug Approvals Will Drive Future Re Rating
Narrative Update on Bayer Analysts have lifted Bayer's blended price target to €40, with many highlighting higher published targets from firms such as DZ Bank, Deutsche Bank, Jefferies and UBS. They are still pointing to litigation outcomes and the asundexian data readout as key swing factors.ナラティブの更新 • May 22
BAYN: Easing Litigation Risks Will Support Re Rating And Future Upside Potential
Analysts have maintained the fair value estimate for Bayer at €60.00 and raised price targets in recent research, citing a series of upgrades, slightly higher assumptions for revenue growth and profit margins, as well as a modestly lower future P/E multiple following a broad reassessment of sector risks and company-specific legal developments. Analyst Commentary Recent research points to a clear shift toward more constructive views on Bayer, with several bullish analysts updating ratings and valuation frameworks in response to company specific developments and sector wide reassessments.
ナラティブの更新 • May 05
BAYN: Future Litigation And Settlement Uncertainty Will Constrain Share Upside Potential
Analysts have nudged the fair value estimate for Bayer higher to about €31.26 from €30.41, citing a series of recent upgrades and higher price targets that reflect updated assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Bayer has been mixed, with several firms updating ratings and price targets over the past few months.ナラティブの更新 • Apr 21
BAYN: Future Litigation Settlement Payouts Will Pressure Upside Potential
Analysts have lifted the Bayer fair value estimate from €23.00 to about €30.41, citing a series of recent price target increases and upgrades that reflect updated assumptions for revenue growth, profit margins, and P/E expectations. Analyst Commentary Recent research on Bayer shows a split in sentiment, with some firms becoming more constructive while others highlight ongoing risks to the investment case.ナラティブの更新 • Apr 06
BAYN: Roundup Settlement Progress Will Reduce Litigation Overhang And Support Future Upside
Analysts maintain a fair value estimate for Bayer at €60.00. Recent adjustments to revenue growth, margin, and P/E assumptions come alongside mixed research actions, including several upgrades that point to potential resolution of litigation overhangs and margin upside, offset by at least one downgrade with a lower price target.ナラティブの更新 • Mar 23
BAYN: Roundup Settlement Advances Will Support Future Upside In Core Earnings
Analysts have modestly adjusted Bayer's price targets to a range of €50 to €55, reflecting mixed views that balance recent upgrades tied to share price weakness, litigation progress and margin potential with at least one more cautious stance. Analyst Commentary Recent research points to a cluster of more optimistic views on Bayer, with several bullish analysts raising ratings or price targets as they reassess litigation risk, product potential and profitability in key segments.ナラティブの更新 • Mar 09
BAYN: Roundup Settlement Progress Will Support Future Upside In Core Earnings
Analysts have revised their view on Bayer with a reduced implied P/E and updated margin expectations, while recent Street research shows a split between a Sell call at €42 and an Overweight stance at €45 that hinges on litigation resolution and potential upside in pharmaceuticals and Crop Science. Analyst Commentary Recent research on Bayer highlights a clear divide between cautious and optimistic views, with valuation closely linked to how investors think litigation, pharmaceutical assets and Crop Science margins will play out.ナラティブの更新 • Feb 23
BAYN: Roundup Settlement Progress Will Unlock Future Equity Upside
The analyst fair value estimate for Bayer has been adjusted to €60 from €55. This reflects updated assumptions on revenue growth and future P/E, alongside mixed Street views, including a downgrade citing valuation risks and an upgrade pointing to potential progress on litigation and margins.ナラティブの更新 • Feb 09
BAYN: Litigation Overhang Resolution Will Unlock Future Equity Upside
Analysts have nudged their Bayer price targets higher, with recent moves such as Barclays shifting to an Overweight rating with a €45 target and Berenberg raising its target to €30.40. They cite potential resolution of litigation issues, along with possible upside in Kerendia and Crop Science margins, as key supports for their updated views.分析記事 • Jan 27
The Market Lifts Bayer Aktiengesellschaft (ETR:BAYN) Shares 29% But It Can Do More
Despite an already strong run, Bayer Aktiengesellschaft ( ETR:BAYN ) shares have been powering on, with a gain of 29...ナラティブの更新 • Jan 25
BAYN: Litigation Resolution And Crop Science Margins Will Unlock Future Upside
Analysts have raised their fair value estimate for Bayer from €47.98 to €55.00, citing the potential resolution of litigation issues, improved expectations for Kerendia, and margin opportunities in the Crop Science business as key supports for the higher target. Analyst Commentary Recent Street research points to a more constructive tone around Bayer, with several bullish analysts adjusting their views in ways that support the higher fair value estimate.
ナラティブの更新 • Jan 09
BAYN: Litigation Overhang Will Drive Future Rerating Risk For Shares
Narrative Update Analysts have nudged their fair value estimate for Bayer from €33.42 to €34.97, citing updated assumptions for modestly higher revenue growth, slightly stronger profit margins, a higher future P/E, and growing confidence that litigation issues, Kerendia expectations, and Crop Science margins could be better than previously modeled. Analyst Commentary Recent Street research on Bayer has focused on how quickly the litigation overhang could be addressed, the role of Kerendia in the pharma portfolio, and the strength of margins in Crop Science.ナラティブの更新 • Dec 26
BAYN Will Rely On Pipeline And Cost Cuts To Unlock Upside Potential
Analysts have raised their price target on Bayer to approximately EUR 48 from around EUR 37. They cite expectations for slightly faster revenue growth, improved profit margins, a modestly lower discount rate and a higher future earnings multiple that together support a higher fair value.ナラティブの更新 • Dec 11
BAYN: Future Litigation Outcomes And Potential Ag Spin-Out Will Shape Shares
Analysts have nudged their Bayer price target higher to about EUR 30 from the mid‑20s, citing slightly faster expected revenue growth, modestly stronger profit margins, and a richer future P/E multiple. Together, these factors lift estimated fair value to roughly EUR 33 per share.分析記事 • Dec 03
Further Upside For Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Introduce Price Risks After 27% Bounce
Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders have had their patience rewarded with a 27% share price jump in the...ナラティブの更新 • Nov 27
BAYN: Future Litigation Decisions And Agriculture Spin-Out Will Guide Shares
Bayer's analyst price target increased from EUR 28.71 to EUR 29.57, as analysts cite improved forecasts for revenue growth and a recent uptick in target valuations across the sector. Analyst Commentary Bullish Takeaways Bullish analysts have raised Bayer's price targets in response to improved revenue forecasts.分析記事 • Nov 14
Bayer Aktiengesellschaft (ETR:BAYN) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a pretty great week for Bayer Aktiengesellschaft ( ETR:BAYN ) shareholders, with its shares surging 13% to...ナラティブの更新 • Nov 13
BAYN: Future Legal Outcomes And Sector Dynamics Will Determine Momentum
Analysts have raised Bayer's price target slightly from $28.53 to $28.71, reflecting steady profit margin improvements and updated industry positioning. This adjustment comes particularly in light of ongoing strategic shifts among major agribusiness peers.分析記事 • Jul 13
Is Bayer (ETR:BAYN) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...株主還元
| BAYN | DE Pharmaceuticals | DE 市場 | |
|---|---|---|---|
| 7D | 1.9% | 1.9% | -2.6% |
| 1Y | 27.4% | 21.1% | -1.4% |
業界別リターン: BAYN過去 1 年間で21.1 % の収益を上げたGerman Pharmaceuticals業界を上回りました。
リターン対市場: BAYN過去 1 年間で-1.4 % の収益を上げたGerman市場を上回りました。
価格変動
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.7% |
安定した株価: BAYN 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BAYNの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1863 | 87,757 | Bill Anderson | www.bayer.com |
バイエルはライフサイエンス企業として世界的に事業を展開している。医薬品、コンシューマーヘルス、クロップサイエンスの各セグメントで事業を展開している。医薬品部門は、主に循環器科と女性医療用の医療用医薬品、腫瘍学、血液学、眼科領域の専門治療薬、画像診断機器と造影剤、細胞治療と遺伝子治療を提供している。コンシューマーヘルス部門は、非処方箋の一般用医薬品、医療用製品、薬用スキンケア製品、栄養補助食品、疼痛・心血管リスク予防製品、消化器系健康製品、アレルギー製品、風邪・咳止め製品を販売している。クロップサイエンス部門は、化学的および生物学的作物保護製品、改良型植物形質、種子、デジタルソリューション、害虫・雑草管理製品、および農業向けカスタマーサービスを提供している。また、種子の育種、増殖、種子ドレッシングを含む種子の生産/加工も行っている。同社は、卸売業者、薬局および薬局チェーン、スーパーマーケット、オンラインおよびその他の小売業者、病院を通じて、また農家に直接製品を販売している。バイエルは1863年に設立され、ドイツのレバークーゼンに本社を置く。
Bayer Aktiengesellschaft 基礎のまとめ
| BAYN 基礎統計学 | |
|---|---|
| 時価総額 | €34.69b |
| 収益（TTM） | -€2.16b |
| 売上高(TTM) | €45.24b |
0.8x
P/Sレシオ-16.1x
PER（株価収益率BAYN は割高か？
公正価値と評価分析を参照収益と収入
| BAYN 損益計算書（TTM） | |
|---|---|
| 収益 | €45.24b |
| 売上原価 | €18.13b |
| 売上総利益 | €27.11b |
| その他の費用 | €29.26b |
| 収益 | -€2.16b |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 04, 2026
| 一株当たり利益（EPS） | -2.19 |
| グロス・マージン | 59.92% |
| 純利益率 | -4.77% |
| 有利子負債／自己資本比率 | 134.3% |
BAYN の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.3%
現在の配当利回り-5%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/10 07:07 |
| 終値 | 2026/06/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bayer Aktiengesellschaft 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。41
| アナリスト | 機関 |
|---|---|
| Rafael Bonardell Trianes | Banco de Sabadell. S.A. |
| Mark Purcell | Barclays |
| Charles Pitman | Barclays |